Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis
In the authors' words
Background: The histopathological diagnosis of challenging melanocytic lesions remains limited by substantial interobserver variability. Although computational pathology foundation models demonstrated promising diagnostic performance, their predictions are often difficult to interpret in terms of established criteria. Objective: We evaluated a diagnostic framework combining foundation-model-based whole-slide image analysis, automated prediction of morphological features, and manually assessed PRAME immunohistochemistry. Methods: Using the Virchow2 foundation model and STAMP framework, we analyzed a retrospective cohort of 1,000 melanocytic lesions undergoing PRAME immunohistochemistry. Models were trained on 800 cases and evaluated on a temporally held-out test cohort of 200 cases. Results: The slide-level malignancy classifier achieved a test AUROC of 0.970 (AUPRC 0.984). Separate models predicted established histopathological criteria with high discrimination, including ulceration (AUROC 0.991) and dermal mitoses (AUROC 0.966). In contrast, predicting PRAME expression from H&E images alone showed lower performance (AUROC 0.776-0.780 for PRAME scores 4 and 0). An integrated model combining the slide-level malignancy score, AI-predicted morphological features, and manual PRAME status achieved an AUROC of 0.972 (AUPRC 0.975), comparable to the standalone classifier. In multivariable analysis, PRAME score 4 versus 0 was strongly associated with malignancy (adjusted OR 35.04, 95% CI 17.39-74.62). Conclusions: These findings demonstrate the feasibility of combining foundation-model-based histopathological analysis with established morphological criteria and PRAME immunohistochemistry. Although the integrated framework did not substantially improve overall discrimination, it provides a structured approach for incorporating complementary histopathological and immunohistochemical information into AI-assisted assessment of melanocytic lesions.
Appeared: Tuesday, November 17. medRxiv. Preprint, not yet peer-reviewed.